Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Silence Therapeutics plcSLN · Entity 5028 | Director · Interim PEO | December 18, 2025 | December 22, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Silence Therapeutics plc
Report date December 18, 2025 · Filed December 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.08 · Expires 2035-12-18 | Direct | 900,000 |
Reported balance
After 2025-12-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-18 · Grant · Acquired 900,000 · Balance 900,000 F1: This option shall vest in equal monthly installments over a one-year period measured from one month following December 18, 2025, subject to the Reporting Person's continuous service as of each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in equal monthly installments over a one-year period measured from one month following December 18, 2025, subject to the Reporting Person's continuous service as of each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2025 Filed Dec 22, 2025 23:04 UTC | Silence Therapeutics plc SLN · Entity 5028 | GrantEmployee Share Option (Right to Buy) · Derivative | 900,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001307218-25-000003 · form4-12222025_111224.xml · derivative · entry 1 Ross Iain · CIK 0001307218 · Director · Interim PEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900,000 Underlying: Ordinary Shares · 900,000 shares Expires 2035-12-18 F1 · derivative.exercise_date: This option shall vest in equal monthly installments over a one-year period measured from one month following December 18, 2025, subject to the Reporting Person's continuous service as of each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:15 UTC | Silence Therapeutics plc SLN · Entity 5028 | GrantShare Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001415889-25-000747 · form4-01062025_040111.xml · derivative · entry 1 Ross Iain · CIK 0001307218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Ordinary Shares · 90,000 shares Expires 2035-01-02 F1 · derivative.exercise_date: This option shall vest in equal monthly installments over a three-year period measured from one month following January 2, 2025, subject to the Reporting Person's continuous service as of each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.